Rep. Quigley Introduces Bill to Reauthorize the ACT for ALS Act Through 2031
This bill is moving forward after a House committee voted to approve it on May 20, 2026. It must now be reported to the full House for further consideration. The bill is actively moving through the legislative process.
This bill is a bipartisan update to a popular existing law. Since both parties usually support ALS research, it has a strong chance of passing through Congress.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
People living with ALS (amyotrophic lateral sclerosis) would benefit from continued federal support for research into new treatments and expanded access to experimental therapies. ALS affects roughly 30,000 Americans at any given time, and this bill keeps the primary federal program focused on ALS treatment development alive through 2031. The broadened clinical trial definitions and enrollment oversight could speed up the path to new drugs reaching patients.
“To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.”
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
The House fast-tracked this bill — limited debate, no amendments allowed, but needs two-thirds support to pass.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
The House fast-tracked this bill — limited debate, no amendments allowed, but needs two-thirds support to pass.
Considered as unfinished business.
U.S. Rep. Ken Calvert (R-CA) and Mike Quigley (D-IL) introduced H.R. 8205 to reauthorize the ACT for ALS Act through 2031. The bill would codify eligibility guidelines for Expanded Access Programs, require a new FDA five-year action plan, and mandate a GAO report on program implementation by 2030.
Congressional deliberations regarding the renewal of the Act for ALS are focusing on overcoming the 'Valley of Death' in drug development. Proponents argue that reauthorization is essential to prioritize early-stage research and streamline the path from breakthroughs to market-ready therapies.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Analysis generated by AI. Always verify with official sources.